Prospective Evaluation of 68Ga-DOTATATE and 18F-DOPA PET Scans in Detecting Tumors Causing Ectopic ACTH Syndrome
Authors' conclusion
DOTA and DOPA improve tumor detection in EAS by increasing Se of structural scans and PPV of detected lesions. The two scans are complementary and should be integral to imaging strategies for EAS. However, DOPA is not currently approved by the Food and Drug Administration for this indication.
Study context
- Population
- Patients with ectopic ACTH syndrome (EAS) from neuroendocrine tumors confirmed by pathology and/or biochemical cure, tertiary referral center, 2014–2024
- Participants
- 24 patients
- Comparison
- 68Ga-DOTATATE PET/CT vs 18F-DOPA PET/CT vs conventional imaging
- Outcome
- Sensitivity and PPV for each imaging modality and 7 combinations, in patients with identified tumors
Methodological detailssingle-centre (tertiary referral center)
- Single-centre (tertiary referral center)
Performance
As reported in the abstract
| Test or model | Sensitivity | Sensitivity, interpreted knowing functional scan results | Sensitivity, without functional scan data | PPV |
|---|---|---|---|---|
| DOPA | 88% (95% CI, 67%-97%)Sensitivity on a scale from 0 to 100 percent | — not stated in the abstract | — not stated in the abstract | — not stated in the abstract |
| Octreoscan (OCT) | 31% (95% CI, 10%-61%)Sensitivity on a scale from 0 to 100 percent | — not stated in the abstract | — not stated in the abstract | — not stated in the abstract |
| DOTA | 79% (95% CI, 57%-92%)Sensitivity on a scale from 0 to 100 percent | — not stated in the abstract | — not stated in the abstract | — not stated in the abstract |
| CT | — not stated in the abstract | 96% (95% CI, 76%-100%) | 57% (95% CI, 35%-76%) | — not stated in the abstract |
| Cardiac CT/MRI | — not stated in the abstract | — not stated in the abstract | — not stated in the abstract | 100% for each |
Sensitivity
DOPA88% (95% CI, 67%-97%)
Octreoscan (OCT)31% (95% CI, 10%-61%)
DOTA79% (95% CI, 57%-92%)
CT— not stated in the abstract
Cardiac CT/MRI— not stated in the abstract
Sensitivity on a scale from 0 to 100 percentSensitivity, interpreted knowing functional scan results
DOPA— not stated in the abstract
Octreoscan (OCT)— not stated in the abstract
DOTA— not stated in the abstract
CT96% (95% CI, 76%-100%)
Cardiac CT/MRI— not stated in the abstract
Sensitivity, without functional scan data
DOPA— not stated in the abstract
Octreoscan (OCT)— not stated in the abstract
DOTA— not stated in the abstract
CT57% (95% CI, 35%-76%)
Cardiac CT/MRI— not stated in the abstract
PPV
DOPA— not stated in the abstract
Octreoscan (OCT)— not stated in the abstract
DOTA— not stated in the abstract
CT— not stated in the abstract
Cardiac CT/MRI100% for each
— not stated in the abstract
- CT/MRI plus DOTA and/or DOPA: PPV; Sensitivity (Se)
- 89%-100%; 64% to 87% (all CIs overlapped)
- Combined CT and MRI without functional scans: PPV; Se
- 79%; 55% (CI overlapped with combinations including DOTA/DOPA)
Original publication
Prospective Evaluation of 68Ga-DOTATATE and 18F-DOPA PET Scans in Detecting Tumors Causing Ectopic ACTH Syndrome. J Clin Endocrinol Metab. Published 28 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →